Plasma sphingolipid abnormalities in neurodegenerative diseases

• DOI: 10.1371/journal.pone.0279315
• Publication Date: 2022-12-16T18:25:07Z
• Authors: Hideki Oizumi; Yoko Sugimura; Tomoko Totsune; Iori Kawasaki; Saki Ohshiro; Toru Baba; Teiko Kimpara; Hiroaki Sakuma; Takafumi Hasegawa; Ichiro Kawahata; Kohji Fukunaga; Atsushi Takeda
• Keywords: Sphingolipid

Background In recent years, there has been increasing evidence that several lipid metabolism abnormalities play an important role in the pathogenesis of neurodegenerative diseases. However, it is still unclear which most Plasma metabolomics (lipidomics) shown to be unbiased method can used explore lipidomics diseases performed only idiopathic Parkinson’s disease (IPD) and Alzheimer’s (AD), comprehensive studies are needed clarify pathogenesis. Methods this study, we investigated plasma lipids using individuals with healthy controls (CNs). was evaluated by liquid chromatography-tandem mass spectrometry (LC–MS/MS) those IPD, dementia Lewy bodies (DLB), multiple system atrophy (MSA), AD, progressive supranuclear palsy (PSP) CNs. Results The results showed (1) sphingosine-1-phosphate (S1P) significantly lower all groups (IPD, DLB, MSA, PSP) than CN group. (2) monohexylceramide (MonCer) lactosylceramide (LacCer) were higher (3) MonCer levels positively correlated LacCer enrolled groups. Conclusion S1P, Glucosylceramide (GlcCer), main component MonCer, sphingolipids biosynthesized from ceramide. Recent have suggested elevated GlcCer decreased S1P neurons related neuronal cell death induce neurodegeneration neuroinflammation. present found diseases, a new finding indicating importance abnormal sphingolipid neurodegeneration.